338 related articles for article (PubMed ID: 32674984)
1. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
[TBL] [Abstract][Full Text] [Related]
2. Physiological and pharmacological characterization of the N1303K mutant CFTR.
DeStefano S; Gees M; Hwang TC
J Cyst Fibros; 2018 Sep; 17(5):573-581. PubMed ID: 29887518
[TBL] [Abstract][Full Text] [Related]
3. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
[TBL] [Abstract][Full Text] [Related]
4. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
[TBL] [Abstract][Full Text] [Related]
5. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
6. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
7. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
8. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
9. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.
Ferreira FC; Buarque CD; Lopes-Pacheco M
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398574
[TBL] [Abstract][Full Text] [Related]
10. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
[TBL] [Abstract][Full Text] [Related]
11. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators.
Laselva O; McCormack J; Bartlett C; Ip W; Gunawardena TNA; Ouyang H; Eckford PDW; Gonska T; Moraes TJ; Bear CE
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33167369
[TBL] [Abstract][Full Text] [Related]
14. CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
Adam D; Bilodeau C; Sognigbé L; Maillé É; Ruffin M; Brochiero E
J Cyst Fibros; 2018 Nov; 17(6):705-714. PubMed ID: 29661510
[TBL] [Abstract][Full Text] [Related]
15. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.
Borgo C; D'Amore C; Capurro V; Tomati V; Sondo E; Cresta F; Castellani C; Pedemonte N; Salvi M
Cell Mol Life Sci; 2022 Mar; 79(4):192. PubMed ID: 35292885
[TBL] [Abstract][Full Text] [Related]
16. Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.
Saint-Criq V; Wang Y; Delpiano L; Lin J; Sheppard DN; Gray MA
J Cyst Fibros; 2021 Sep; 20(5):843-850. PubMed ID: 34020896
[TBL] [Abstract][Full Text] [Related]
17. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
[TBL] [Abstract][Full Text] [Related]
18. Ion Channel Modulators in Cystic Fibrosis.
Gentzsch M; Mall MA
Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
[TBL] [Abstract][Full Text] [Related]
19. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
[TBL] [Abstract][Full Text] [Related]
20. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
